 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...7891011121314151617...3839» |
- UTILIZATION OF BIOLOGIC AGENTS AMONG HISPANIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW UPDATES (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_3146;
This relatively high rate of biologic use is associated with less steroid use, lower ED use, and may result in less active disease. The difference between our study findings and prior work could be unique to our Florida-based study population or represent improved healthcare over time in this traditionally vulnerable group.
- CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1706;
There were no differences in the utilization of IBD DMTs including mesalamine, azathioprine, anti-TNFs (infliximab, adalimumab, certolizumab pegol), and vedolizumab between the two groups.Three months after any IBD therapy initiation, UC patients with MS had higher all-cause mortality (OR: 1.87) and were more likely to need steroids (OR: 1.4) and plasma exchange...Natalizumab is indicated in both Crohn’s disease and MS and may also become an effective DMT for patients with both UC and MS. Future directions include stratifying disease outcomes based on different DMT utilization.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH CHRON’S DISEASE AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1705;
CD patients with MS were also more likely to use the following MS DMTs: natalizumab, glatiramer, interferon beta-1a and 1b, fingolimod, teriflunomide, dimethyl fumarate, ocrelizumab, and ofatumumab (Table 1).Three months after any IBD therapy initiation, CD patients with MS were more likely to need plasma exchange and undergo small intestine resections but were less likely to have fistulizing disease...Interestingly, they were also more likely to be prescribed TNF alpha-inhibitors. Future directions include stratifying the association with anti-TNFs from a temporal perspective and in terms of IBD and MS severity.
- Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
PERSISTENCE AND OTHER TREATMENT PATTERNS AMONG BIO-EXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB OR ADALIMUMAB (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1669;
Similar proportions in the ustekinumab vs adalimumab cohort switched to a new biologic (5.7% vs 7.9%) and, among those who discontinued, restarted index biologic (26.7% vs 25.9%) at 12 months post-index and post-discontinuation, respectively. Bio-experienced adults with CD initiated on ustekinumab relative to adalimumab were significantly more persistent and had similar rates of switching and restart.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa. (Pubmed Central) - Apr 22, 2022
Bio-experienced adults with CD initiated on ustekinumab relative to adalimumab were significantly more persistent and had similar rates of switching and restart. No abstract available
- Identification of anti-cytokine autoantibodies with potential to predict flare in rheumatoid arthritis patients undergoing biological therapies: A discovery study (Poster View 1) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1729;
These patients were treated with TNF inhibitors (Etanercept, N=47; Infliximab, N=12; Adalimumab, N=35; Certolizumab (CTZ), N=17; Golimumab, N=5), Tocilizumab (TCZ, N=60) and Abatacept (ABA, N=18). Although further validation of our results is needed, we present a ground-breaking study showing the potential of anti-IL17A, anti-IL-1α, and anti-IL18 to predict flare in RA patients under biological therapies.
- SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES. 10 YEARS OF REAL-LIFE DATA. BIOABASAR 3.0 REGISTRY (Poster View 3) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1650;
This could be related to the fact that the use of steroids is frequently associated with active disease or severe conditions. Exposed patients have a lower AE-free survival and a lower treatment survival.
- Tumor Necrosis Factor blockers induced sarcoidosis: description of 31 cases from the French Pharmacovigilance Database (Poster View 3) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1648;
Data were obtained from 2002 to 2019 for infliximab, adalimumab, golimumab, certolizumab and etanercept...The culprit drug was discontinued in 26 (84%) patients, and a double-barreled inflammatory gun to control both initial and induced disorders was proposed in 19 of them (90.5 %), mostly glucocorticoids (n=13, 68.4%) alone or combined with methotrexate (n=3, 15,8%)... This second largest case-series shows that TIS are mostly encountered with etanercept, but without any difference in clinical or prognostic implications with the other TNFb-subclasses.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Does TNF inhibitors molecular structure matter? Analysis of Impact of baseline Rheumatoid Factor titers on drug levels in patients with Rheumatoid Arthritis (Poster View 3) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1637;
A concentration-response association has been clearly established for TNFi, and baseline RF levels appear to influence drug levels. Reduced immune complexes formation with CZP may result in a limited impact of baseline RF titers on drug levels.
- Comorbidities in rheumatoid arthritis do not influence biologics drug retention: Data from the National Health Insurance Fund of Tunis (Poster View 3) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1602;
Comorbidities can have an impact not only on our therapeutic choice but also on the efficacy and maintenance of biomedicines as well as the quality of life of patients and consequently the prognosis of RA (1). The few studies that have looked at this subject have produced variable results.
- Assessment of the Swollen to Tender Joint Count Ratio as a Predictor of Response in Rheumatoid Arthritis Patients: a Cohort Study (Poster View 2) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1549;
Two hundred and sixty-nine (93.7%) were on csDMARD; with regard to b/tsDMARD therapy, 66 started etanercept (23.0%), 62 tocilizumab (21.6%), 58 rituximab (20.2%), 44 adalimumab (15.3%), 17 golimumab (5.9%), 14 abatacept (4.9%), 7 certolizumab (2.4%), 5 upadacitinib and baricitinib (1.7%), 4 infliximab (1.4%), 3 tofacitinib (1.0%), and 2 anakinra (0.7%). The STR is a practical, easy-to-use index that can be used as an adjunct in clinical practice in the evaluation of patients with rheumatoid arthritis, as it is associated with a better response to b/tsDMARD therapy, regardless of patient status and therapy, although it should not be used alone, as it does not appear to be a predictor of response, according to the indices that are currently used.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Plasma Calprotectin Was Assessed In Multiple Biological Treatment Strategies For Early Rheumatoid Arthritis (Poster View 2) - Apr 21, 2022 - Abstract #EULAR2022EULAR_1505;
The decline differed between treatment groups and was largest in patients treated with a TNF inhibitor and methotrexate, suggesting that calprotectin reflects the activity of specific inflammatory pathways rather than overall inflammation. The findings of this study should be further explored.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Journal: A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population. (Pubmed Central) - Apr 19, 2022
Two SNPs near spondin-1 and semaphorin-4G approached genome-wide significance. The results of the current study did not provide an unambiguous predictor of CZP response.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome. (Pubmed Central) - Apr 19, 2022
Oral therapies include amitriptyline, hydroxyzine, cyclosporine A, and pentosan polysulfate sodium (PPS), although the recent finding of pigmented maculopathy with chronic PPS is very concerning and must be discussed with patients, many of whom will choose to either come off this medicine or not even start it. Certolizumab pegol is a pharmacologic therapy that is currently in clinical development for treatment of IC/BPS symptoms.
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Retrospective data, Journal: Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients. (Pubmed Central) - Apr 14, 2022
This large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab.
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: I do not recommend switching biologics due to pregnancy if in remission. Nearly no transfer of Cimzia to the foetus in contrast to the other biologics. But all biologics are safe in pregnancy. No risk of infant infection and normal development! Healthy mum = healthy baby👶🏼 (Twitter) - Apr 13, 2022
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
There's ⬇️ understanding about biologics and pregnancy. Cimzia recommended because of less crossing the placenta and in human milk. But we know, thanks to Dr Mahadevan and co-authors, that switching is not needed. The docs are not up-to-date. Especially rheumatologists, frankly. (Twitter) - Apr 13, 2022
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal, HEOR: Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol. (Pubmed Central) - Apr 12, 2022
The subjects of the study showed a significantly lower quality of life than the general population despite effective control of the disease. Two- part models facilitate the interpretation of quality-of-life studies using the EQ- 5D.
- || Review, Journal: Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. (Pubmed Central) - Apr 7, 2022
Two- part models facilitate the interpretation of quality-of-life studies using the EQ- 5D. Despite similar efficacy for ACR response, IL-17A and IL-17RA inhibitors and guselkumab offered preferential efficacy to anti-TNFs in skin manifestations, and for enthesitis and dactylitis, thereby supporting drug selection based on predominant clinical phenotype.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical data, P3 data, Journal: Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. (Pubmed Central) - Apr 6, 2022
P, P3
CZP treatment was well tolerated up to 3 years, with no new safety signals versus previous reports. Clinical outcomes achieved after 1 year were sustained to 3 years.
- Longitudinal investigation and visualization of course and burden of adverse drug reactions in patients with inflammatory rheumatic diseases using TNFα inhibitors (Poster Tour Auditorium 1) - Apr 4, 2022 - Abstract #EULAR2022EULAR_1431;
Infections have the highest burden at start but decrease over time and most of them resolve during follow-up. Injection site reactions are mostly recurrent with a low and stable burden over time.
- methotrexate / Generic mfg.
Can Patients with Controlled RA Receiving any class of Targeted Therapy with Methotrexate (MTX) Sustain Disease Control after Tapering MTX? A Systematic Review and Meta-analysis (Poster Tour Auditorium 11) - Apr 4, 2022 - Abstract #EULAR2022EULAR_1360;
This review may inform patients with controlled disease on any of a range of targeted therapies and MTX, but who are struggling with MTX-related adverse effects and wish to taper it. Longer follow-up studies with attention to radiographic, functional and patient reported outcomes are needed.
- Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
GENETIC INVESTIGATION OF TUMOUR NECROSIS FACTOR INHIBITOR IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (Poster Tour Auditorium 4) - Apr 4, 2022 - Abstract #EULAR2022EULAR_1070;
The current study increases the evidence for association between immunogenicity development with HLA-DQA1 and HLA-DRB1 alleles in patients receiving monoclonal antibody derived TNFi therapy. Further well powered studies are now required to determine the utility of HLA markers as a potential tool to aid the clinical management of RA.
- Comparison of major cardiovascular and thromboembolic events in safety reports between rheumatoid arthritis patients treated with JAK-inhibitors versus anti-TNF: results from VigiBase® (Congress Hall A2) - Apr 4, 2022 - Abstract #EULAR2022EULAR_907;
We selected reports in Vigibase of patients aged between 18 and 75 years, between 01/01/2011 and 12/31/2020, with JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) or anti-TNF (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab) with a diagnosis of RA. Based on real-world data, the analysis did not identify an increase of declaration of MACEs with JAK-inhibitor compared to anti-TNF whereas we could observe more than three times declarations of VTE in Vigibase with JAK-inhibitors compared to anti-TNF.
- Treatment discontinuation due to adverse events as an overall measure of tolerance and safety of JAK-inhibitors: An international collaboration of registries of rheumatoid arthritis patients (the “JAK-pot” study). (Congress Hall A2) - Apr 4, 2022 - Abstract #EULAR2022EULAR_905;
After adjusting for potential confounders, the rate of treatment discontinuation for AEs was comparable between JAKi and OMA or TNFi. Treatment discontinuation for AEs comprises a wide range of AEs; future analyses will be performed to investigate specific AEs, such as cancer, serious infections or major adverse cardiovascular events.
- Serious Infections in Offspring Exposed to Tumour Necrosis Factor Inhibitors During Pregnancy: Comparison of Agents with Low and High Placental Transfer (Auditorium 12) - Apr 4, 2022 - Abstract #EULAR2022EULAR_855;
Exposure was further categorized into high (i.e. infliximab, adalimumab, golimumab) and low (i.e. certolizumab, etanercept) placental transfer ability. Although children exposed to high transfer TNFi may have a higher risk of serious infection, we saw no clear excess risk of serious infections in children exposed in utero to TNFi with high versus low placental transfer due to the wide confidence interval.
- Benlysta (belimumab) / GSK, Entyvio (vedolizumab) / Takeda, Cimzia (certolizumab pegol) / Astellas, UCB
Reported congenital malformations after exposure to non-TNF-α inhibitors: a retrospective comparative study in Eudravigilance database (Auditorium 12) - Apr 4, 2022 - Abstract #EULAR2022EULAR_854;
Except for vedolizumab, no special safety signal was identified regarding occurrence of CMs after exposure to non-TNFis. Based on available information, no firm conclusions can be made regarding observed CCA cases in vedolizumab group.
- Real-world Evidence on Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry (Poster Tour Auditorium 12) - Apr 4, 2022 - Abstract #EULAR2022EULAR_737;
IL-17 initiators had high skin disease (BSA ≥10%) more often and initiated as first-line therapy less frequently than TNFi initiators. Assessing all PsA domains is important for optimal disease management.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Profound anticoagulant effects of initial antirheumatic treatments in early rheumatoid arthritis patients; a NORD-STAR spin-off study (Congress Hall A2) - Apr 4, 2022 - Abstract #EULAR2022EULAR_663;
Our results indicate an enhanced coagulation and fibrinolytic impairment in newly diagnosed RA patients. Effective antirheumatic treatments reduce this hemostatic imbalance, with significantly more pronounced effects of biologic drugs compared to conventional (MTX+glucocorticoids) treatment.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Certolizumab-pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: Clinical and radiographic 48-weeks results of the investigator-initiated randomized NORD-STAR trial (Congress Hall A2) - Apr 4, 2022 - Abstract #EULAR2022EULAR_662;
P4
Radiographic progression was low and similar between treatments. Figure 1.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells. (Pubmed Central) - Apr 2, 2022
We therefore demonstrate that pegylation diminishes antigen capture by dendritic cells, peptide presentation to T-cells and T-cell priming. This mechanism might reduce immunogenicity and contribute to the long half-life of CZP and possibly of other pegylated molecules.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Rheumatic Diseases in Reproductive Age-the Possibilities and the Risks. (Pubmed Central) - Apr 2, 2022
Corticosteroids should be tapered, and other biologics should be avoided due to teratogenicity or carefully administered due to the impact on the fetal immune system. Distinguishing between disease flare and obstetrical complications can be difficult in clinical practice; however, some clinical symptoms and serological markers can be helpful in the differential diagnosis.
- | New trial, Metastases: Stand UP to Rheumatoid Arthritis (SUPRA) (clinicaltrials.gov) - Mar 31, 2022
P=N/A, N=75, Not yet recruiting, Sponsor: Marie Hudson, MD
- || Clinical, Journal: Drug Survival of Biologics in Patients With Hidradenitis Suppurativa. (Pubmed Central) - Mar 26, 2022
In this cohort study, drug survival was comparable between adalimumab, infliximab, and ustekinumab but significantly lower for etanercept. There were no differences in drug survival among biologic-naive and nonnaive patients.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial () - Mar 21, 2022 - Abstract #AAD2022AAD_2550;
P3
Data are reported from the CIMPACT (NCT02346240) phase 3 trial; study design reported previously.[1,2] Patients were randomized to CZP 400mg every 2 weeks (wks)(Q2W), CZP 200mg Q2W (400mg at Wks0/2/4), placebo, or etanercept (ETN). CZP treatment was associated with numerical improvements in FASca scores over 3 years, with numerically larger CfB observed for CZP 400mg Q2W at Wks16/48.
- Cimzia (certolizumab pegol) / Astellas, UCB
Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2) () - Mar 21, 2022 - Abstract #AAD2022AAD_2547;
P3
CZP treatment was associated with improvement in HADS-Anxiety and HADS-Depression scores at Wk48 and Wk144 for patients with moderate to severe anxiety or depression at baseline. These analyses are limited by the small number of patients enrolled with moderate to severe anxiety or depression.
- Real-World Data Study in Healthcare Costs From Adults With Psoriasis Who Initiated Treatment With Apremilast or Biologics () - Mar 21, 2022 - Abstract #AAD2022AAD_2533;
At 24 months, only patients who initiated apremilast and switched had higher direct healthcare costs than those who discontinued or persisted. Patients who initiated on biologics and were persistent, had the highest costs.
- Real-World Treatment Patterns of Adults With Psoriasis Initiated on Apremilast or Biologics (Poster Presentation Center 2) - Mar 21, 2022 - Abstract #AAD2022AAD_2098;
Oral treatments had lower switch rates compared with TNFi despite lower effectiveness in biologic-naive patients. Discontinuation was higher and persistency was lower for apremilast than for more effective biologic treatments.
- Cimzia (certolizumab pegol) / Astellas, UCB
Adoption of newly FDA-approved targeted immunomodulatory therapies for Plaque Psoriasis by Dermatologists: an analysis of Medicare Part D claims from 2013-2018. () - Mar 21, 2022 - Abstract #AAD2022AAD_2001;
The adoption of novel treatments for psoriasis by dermatologists who provide care to the Medicare population may be influenced by time in practice and practice volume. There is a paucity of dermatologist prescribers of novel biologics in non-metropolitan areas to Medicare beneficiaries.
- A case of a paradoxical palmoplantar pustular psoriasis associated with certolizumab pegol () - Mar 20, 2022 - Abstract #INDERCOS2022INDERCOS_9;
Methotrexate treatment was also discontinued and topical calcipotriol betamethasone combination and moisturizer were recommended...The majority of reported cases are associated with infliximab, adalimumab, and etanercept...In some of reported cases, there was scalp involvement accompanied by alopecia, which was seen at a later stage in our case. It is thought that this case will contribute to the literature with these aspects.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Optic Neuritis Associated With Tumor Necrosis Factor-Alpha Inhibitor Certolizumab. (Pubmed Central) - Mar 19, 2022
It is thought that this case will contribute to the literature with these aspects. No abstract available
- | Journal: Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab. (Pubmed Central) - Mar 19, 2022
No abstract available The efficacy and safety outcomes and drug survival rates seem to be similar for TNF inhibitors and tocilizumab in patients with Takayasu arteritis.
- || Review, Journal: Pharmacological treatment of COVID-19: an opinion paper. (Pubmed Central) - Mar 18, 2022
The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
- | Journal: Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? (Pubmed Central) - Mar 18, 2022
All patients underwent vaccination for SARS-CoV-2 with mRNA BNT162b2 vaccine...As for other rheumatic diseases on immunomodulatory treatment, our data showed a reduced humoral response in PsA patients compared to the control group. However, antibody response did not significantly differ between groups treated with different medications.
- | Journal: Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. (Pubmed Central) - Mar 16, 2022
However, antibody response did not significantly differ between groups treated with different medications. Compliance with the EULAR-PtC results in absence or low levels of TNFi in cord blood.
- || Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. (Pubmed Central) - Mar 15, 2022
Compliance with the EULAR-PtC results in absence or low levels of TNFi in cord blood. These findings indicate that circulating proportions PD-1+TFh and CTLA-4+ conventional CD4+ T cells at baseline may serve as predictive biomarkers for remission in early RA after CTLA-4Ig treatment.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Good discussion. The view from Rheumatology (using specialty drugs to reduce pain/prevent disability) 1. Utilization mgmt enforces an auction for top tier coverage; highest rebate to #PBM earns coverage & pushes drug price higher. Cheaper specialty drugs never covered (eg Cimzia) (Twitter) - Mar 12, 2022
- | Journal: Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. (Pubmed Central) - Mar 11, 2022
It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
- | Retrospective data, Journal: Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study. (Pubmed Central) - Mar 9, 2022
The finding was consistent across all IA indications. Hence, patients who discontinue their first-line treatment may still benefit from treatment with an alternative SC-TNFi as a second-line therapy in IA.
- Efficacy of Biologics and Targeted Synthetic Drugs Approved in Russia to Treat Adults with Active Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1423;
We conducted a systematic search for RCTs evaluating the efficacy of biologics (adalimumab, golimumab, levilimab, olokizumab, sarilumab, tocilizumab, infliximab, rituximab, certolizumab pegol, abatacept and etanercept) and tsDMARDs (tofacitinib, baricitinib and upadacitinib), both in combination with conventional synthetic DMARDs (csDMARDs) and in monotherapy for the treatment of adults with active RA...The proportion of patients with an inadequate response to previous methotrexate therapy was at least 50% in the included RCTs...Conclusion. Given the predominantly comparable relative effectiveness of the analyzed drugs, health professionals should also consider other factors, when choosing a treatment option for adults with active RA.